Ascendis Pharma Reports Second Quarter 2024 Financial Results
Ascendis Pharma reported Q2 2024 financial results and provided a business update. Key highlights:
1. YORVIPATH approved by FDA for hypoparathyroidism in adults
2. TransCon CNP pivotal trial results expected soon
3. SKYTROFA Q2 revenue of €26 million, 134% YoY volume growth
4. Full year 2024 SKYTROFA revenue outlook revised to €220-240 million
5. Q2 total revenue: €36 million, down from €47.4 million in Q2 2023
6. Net loss of €109.4 million or €1.91 per share
7. Cash position of €259 million as of June 30, 2024
The company expects to be operating cash flow breakeven on a quarterly basis in 2024 or 2025, pending YORVIPATH launch timing in the U.S.
Ascendis Pharma ha annunciato i risultati finanziari del secondo trimestre 2024 e fornito un aggiornamento sull'attività. Principali punti salienti:
1. YORVIPATH approvato dalla FDA per l'ipoparatiroidismo negli adulti
2. Risultati dello studio pivotale di TransCon CNP attesi a breve
3. Fatturato di SKYTROFA nel secondo trimestre pari a 26 milioni di euro, con una crescita del volume del 134% rispetto all'anno precedente
4. Previsione di fatturato per l'intero anno 2024 di SKYTROFA rivista a 220-240 milioni di euro
5. Fatturato totale del secondo trimestre: 36 milioni di euro, in calo rispetto ai 47,4 milioni di euro del secondo trimestre 2023
6. Perdita netta di 109,4 milioni di euro, pari a 1,91 euro per azione
7. Posizione di cassa di 259 milioni di euro al 30 giugno 2024
La società prevede di raggiungere il pareggio operativo trimestrale nel 2024 o 2025, a seconda della tempistica del lancio di YORVIPATH negli Stati Uniti.
Ascendis Pharma reportó los resultados financieros del segundo trimestre de 2024 y proporcionó una actualización de negocios. Puntos destacados:
1. YORVIPATH aprobado por la FDA para hipoparatiroidismo en adultos
2. Resultados del ensayo pivotal de TransCon CNP se esperan pronto
3. Ingresos de SKYTROFA en el segundo trimestre de 26 millones de euros, crecimiento de volumen del 134% en comparación anual
4. Perspectiva de ingresos revisada para el año completo 2024 de SKYTROFA a 220-240 millones de euros
5. Ingresos totales del segundo trimestre: 36 millones de euros, en descenso desde los 47,4 millones de euros del segundo trimestre de 2023
6. Pérdida neta de 109,4 millones de euros, o 1,91 euros por acción
7. Posición de efectivo de 259 millones de euros a 30 de junio de 2024
La compañía espera alcanzar el punto de equilibrio de flujo de efectivo operativo de forma trimestral en 2024 o 2025, dependiendo del momento del lanzamiento de YORVIPATH en Estados Unidos.
Ascendis Pharma는 2024년 2분기 재무 결과를 보고하고 비즈니스 업데이트를 제공했습니다. 주요 하이라이트:
1. YORVIPATH가 성인 저부갑상선증에 대해 FDA의 승인을 받았습니다.
2. TransCon CNP의 주요 임상 시험 결과가 곧 발표될 예정입니다.
3. SKYTROFA의 2분기 매출은 2,600만 유로로, 전년 대비 134%의 증가율을 기록했습니다.
4. 2024년 전체 SKYTROFA 매출 전망이 2억 2천만에서 2억 4천만 유로로 수정되었습니다.
5. 2분기 총 매출: 3,600만 유로, 2023년 2분기 4,740만 유로에서 감소했습니다.
6. 순손실은 1억 940만 유로로, 주당 1.91 유로입니다.
7. 2024년 6월 30일 기준 현금 보유액은 2억 5천 9백만 유로입니다.
회사는 YORVIPATH의 미국 출시 시기에 따라 2024년 또는 2025년에 분기별 운영 현금 흐름 손익 분기점을 달성할 것으로 예상하고 있습니다.
Ascendis Pharma a publié les résultats financiers du deuxième trimestre 2024 et a fourni une mise à jour sur les activités. Points clés:
1. YORVIPATH approuvé par la FDA pour l'hypoparathyroïdie chez les adultes
2. Résultats de l'essai pivot de TransCon CNP attendus sous peu
3. Chiffre d'affaires de SKYTROFA au deuxième trimestre de 26 millions d'euros, croissance de volume de 134 % par rapport à l'année précédente
4. Perspectives de chiffre d'affaires pour l'année complète 2024 de SKYTROFA révisées à 220-240 millions d'euros
5. Chiffre d'affaires total du deuxième trimestre : 36 millions d'euros, en baisse par rapport à 47,4 millions d'euros au deuxième trimestre 2023
6. Perte nette de 109,4 millions d'euros, soit 1,91 euro par action
7. Position de trésorerie de 259 millions d'euros au 30 juin 2024
La société s'attend à atteindre un flux de trésorerie opérationnel équilibré sur une base trimestrielle en 2024 ou 2025, en fonction du calendrier de lancement de YORVIPATH aux États-Unis.
Ascendis Pharma hat die finanziellen Ergebnisse für das zweite Quartal 2024 veröffentlicht und ein geschäftliches Update bereitgestellt. Wichtige Höhepunkte:
1. YORVIPATH von der FDA für hypoparathyreoidismus bei Erwachsenen zugelassen
2. Ergebnisse der entscheidenden Studie zu TransCon CNP werden bald erwartet
3. SKYTROFA erzielte im 2. Quartal einen Umsatz von 26 Millionen Euro, was einem volumenmäßigen Wachstum von 134% im Jahresvergleich entspricht
4. Der Ausblick für den SKYTROFA Umsatz für das gesamte Jahr 2024 wurde auf 220-240 Millionen Euro nach unten korrigiert
5. Gesamter Umsatz im 2. Quartal: 36 Millionen Euro, Rückgang von 47,4 Millionen Euro im 2. Quartal 2023
6. Nettoverlust von 109,4 Millionen Euro oder 1,91 Euro pro Aktie
7. Liquiditätsposition von 259 Millionen Euro am 30. Juni 2024
Das Unternehmen erwartet, im Kalenderjahr 2024 oder 2025 einen quartalsweisen positiven Cashflow zu erreichen, abhängig vom Zeitpunkt des YORVIPATH-Starts in den USA.
- YORVIPATH approved by FDA as first treatment for hypoparathyroidism in adults
- SKYTROFA Q2 volume growth of 134% year-over-year
- SKYTROFA achieved U.S. market value leadership
- Entered $150 million capped synthetic royalty funding agreement with Royalty Pharma for YORVIPATH
- Expect to be operating cash flow breakeven on a quarterly basis in 2024 or 2025
- SKYTROFA Q2 revenue decreased 27% year-over-year to €26.2 million
- Negative adjustment of €27.1 million to prior period sales deductions for SKYTROFA
- Revised full year 2024 SKYTROFA revenue outlook to €220-240 million
- Net loss of €109.4 million in Q2 2024
- Cash position decreased from €399 million to €259 million since December 31, 2023
Insights
Ascendis Pharma's Q2 2024 results present a mixed picture. Revenue decreased 27% YoY to €26.2 million, primarily due to a €27.1 million negative adjustment related to market access improvements. However, SKYTROFA saw impressive 134% YoY volume growth. The company has revised its 2024 SKYTROFA revenue outlook to €220-240 million.
The FDA approval of YORVIPATH is a significant milestone, potentially opening a new revenue stream. However, the delay in commercial availability until Q1 2025 may impact near-term financials. The €150 million royalty agreement with Royalty Pharma provides additional liquidity but comes with future obligations.
While R&D costs decreased, SG&A expenses increased due to commercial expansion. The company's cash position of €259 million is concerning given the high burn rate, although management expects to reach operating cash flow breakeven by 2024 or 2025.
Ascendis Pharma's pipeline progress is noteworthy. The FDA approval of YORVIPATH as the first treatment for adult hypoparathyroidism addresses a significant unmet need. The upcoming TransCon CNP (navepegritide) pivotal trial results could potentially expand their rare disease portfolio further.
The company's TransCon technology platform continues to yield results, with two out of three Endocrine Rare Disease candidates now FDA-approved. The ongoing trials for TransCon hGH in adult growth hormone deficiency and Turner syndrome could broaden its application.
In oncology, the 40% response rate in anti-PD-1 refractory melanoma patients treated with TransCon IL-2 β/γ and TransCon TLR7/8 Agonist combination is promising, albeit in a small sample. The upcoming ESMO presentation on TransCon IL-2 β/γ in platinum-resistant ovarian cancer will be important for assessing its potential in this difficult-to-treat population.
- YORVIPATH approved by U.S. Food & Drug Administration (FDA) as the first and only treatment of hypoparathyroidism in adults
- TransCon CNP (navepegritide) pivotal ApproaCH Trial topline results expected in the coming weeks
- SKYTROFA Q2 revenue of
€26 million –134% year-over-year volume growth offset by negative adjustment of€27 million , resetting market access for continued growth - Revising full year 2024 SKYTROFA revenue outlook to
€220 -€240 million - Conference call today at 4:30 pm ET
COPENHAGEN, Denmark, Sept. 03, 2024 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced financial results for the second quarter ended June 30, 2024, and provided a business update.
“The recent FDA approval of YORVIPATH demonstrates why our unrelenting focus on helping patients suffering from hypoparathyroidism and other serious diseases with considerable unmet need is so important for Ascendis,” said Jan Mikkelsen, Ascendis Pharma’s President and Chief Executive Officer. “Already, two out of our three Endocrine Rare Disease TransCon product candidates have been approved by the FDA and European Commission. Our first, SKYTROFA, has achieved U.S. market value leadership, and, we believe, now with broader market access, remains well positioned to reach blockbuster status in the U.S. alone. Looking forward, we are preparing for our second U.S. launch with YORVIPATH and are on track to report pivotal data in the coming weeks for our third TransCon product candidate, TransCon CNP.”
Select Highlights & Anticipated 2024 Milestones
- TransCon hGH:
(lonapegsomatropin, marketed as SKYTROFA)- SKYTROFA revenue for the second quarter of 2024 totaled
€26.2 million , a27% year-over-year decrease compared to€35.9 million during the same period in 2023.134% year-over-year volume growth was offset by the cost associated with broader market access for SKYTROFA which also resulted in a negative adjustment to prior period sales deductions of€27.1 million , where€19.5 million and€7.6 million were attributable to the three months ended March 31, 2024, and periods prior to January 1, 2024, respectively. - SKYTROFA revenue for the first half of 2024 totaled
€91.2 million , a35% year-over-year increase compared to€67.4 million during the same period of 2023.159% year-over-year volume growth was offset by the cost associated with broader market access for SKYTROFA which also resulted in a negative adjustment to prior period sales deductions of€7.6 million , which were attributable to periods prior to January 1, 2024. - On track to submit a supplemental Biologics License Application to the FDA for adult growth hormone deficiency in the third quarter of 2024.
- Topline results from Phase 2 New InsiGHTS Trial in Turner syndrome expected in the fourth quarter of 2024.
- SKYTROFA revenue for the second quarter of 2024 totaled
- TransCon PTH:
(palopegteriparatide, marketed as YORVIPATH)
- Received U.S. FDA approval for TransCon PTH, under the brand name YORVIPATH, for the treatment of hypoparathyroidism in adults.
- Completing manufacturing of commercial product for the U.S. market and anticipate initial supply will be available in the first quarter of 2025. The Company is in dialogue with the FDA about commercialization of existing manufactured product, which if agreed, could be introduced in the U.S. in the fourth quarter of 2024.
- Second quarter YORVIPATH revenue totaled
€5.2 million , reflecting the first full quarter of commercial launch in Germany and Austria as well initial revenue in International Markets. Initial revenue in France expected starting in the fourth quarter of 2024.
- TransCon CNP
(navepegritide)- Topline data from pivotal ApproaCH Trial expected in the coming weeks, and, if successful, plan to submit a New Drug Application to FDA for children with achondroplasia (age 2-11 years) in the first quarter of 2025.
- Plan to complete enrollment in the combination TransCon hGH and TransCon CNP COACH trial of children with achondroplasia (ages 2-11 years) during the third quarter of 2024; topline Week 26 data expected in the second quarter of 2025.
- Expect to initiate teACH, a Phase 2 trial in adolescents with achondroplasia, in the fourth quarter of 2024.
- Oncology Programs
- Presented new and updated results from the ongoing Phase 1/2 IL-Believe Trial of TransCon IL-2 β⁄γ in a poster presentation at ASCO 2024. As of the April 16, 2024, data cutoff,
40% of efficacy-evaluable patients (2 out of 5) in the initial cohort of patients with anti-PD-1 refractory melanoma treated with TransCon IL-2 β⁄γ in combination with TransCon TLR7/8 Agonist exhibited confirmed clinical responses with no new safety signals. - Initial results from the Phase 2 dose expansion cohort of the IL-Believe Trial of TransCon IL-2 β⁄γ in combination with chemotherapy in platinum-resistant ovarian cancer (PROC) will be presented later this month at the European Society for Medical Oncology (ESMO) 2024 Congress in Barcelona, Spain.
- Presented new and updated results from the ongoing Phase 1/2 IL-Believe Trial of TransCon IL-2 β⁄γ in a poster presentation at ASCO 2024. As of the April 16, 2024, data cutoff,
- Financial Update and Outlook Based on Current Plans
- As of June 30, 2024, Ascendis Pharma had cash, cash equivalents, and marketable securities totaling
€259 million , compared to€399 million as of December 31, 2023. - Full year 2024 SKYTROFA revenue expected to be
€220 million to€240 million . - Expect total operating expenses (SG&A and R&D) to be approximately
€600 million for 2024. - Pending launch timing of YORVIPATH in the U.S., expect to be operating cash flow breakeven on a quarterly basis in 2024 or 2025
- Subsequent to the quarter end, entered into a
$150 million capped synthetic royalty funding agreement with Royalty Pharma relating to net sales of YORVIPATH in the United States. More information on this funding can be found in a separate press release issued today and available here on the Investors & News section of the Ascendis Pharma website.
- As of June 30, 2024, Ascendis Pharma had cash, cash equivalents, and marketable securities totaling
Second Quarter 2024 Financial Results
Total revenue for the second quarter of 2024 was
| Total Revenue (In EUR'000s) | Three Months Ended June 30, | Six Months Ended June 30, | ||||||
| 2024 | 2023 | 2024 | 2023 | |||||
| Revenue from external customers | ||||||||
| Commercial sale of products | 31,389 | 35,895 | 97,888 | 67,446 | ||||
| Licenses | 869 | 589 | 25,639 | 1,203 | ||||
| Other | 3,740 | 10,909 | 8,365 | 12,333 | ||||
| Total revenue from external customers | 35,998 | 47,393 | 131,892 | 80,982 | ||||
Research and development (R&D) costs for the second quarter of 2024 were
Selling, general, and administrative (SG&A) expenses for the second quarter of 2024 were
Total operating expenses for the second quarter of 2024 were
Net finance income for the second quarter of 2024 was
For the second quarter of 2024, Ascendis Pharma reported a net loss of
As of June 30, 2024, Ascendis Pharma had cash, cash equivalents, and marketable securities totaling
Conference Call and Webcast Information
Ascendis Pharma will host a conference call and webcast today at 4:30 pm Eastern Time (ET) to discuss its second quarter 2024 financial results.
Those who would like to participate may access the live webcast here, or register in advance for the teleconference here. The link to the live webcast will also be available on the Investors & News section of the Ascendis Pharma website at https://investors.ascendispharma.com. A replay of the webcast will be available on this section of the Ascendis Pharma website shortly after conclusion of the event for 30 days.
About Ascendis Pharma A/S
Ascendis Pharma is applying its innovative TransCon technology platform to build a leading, fully integrated biopharma company focused on making a meaningful difference in patients’ lives. Guided by its core values of Patients, Science, and Passion, Ascendis uses its TransCon technologies to create new and potentially best-in-class therapies. Ascendis is headquartered in Copenhagen, Denmark and has additional facilities in Europe and the United States. Please visit ascendispharma.com to learn more.
Forward-Looking Statements
This press release contains forward-looking statements that involve substantial risks and uncertainties. All statements, other than statements of historical facts, included in this press release regarding Ascendis’ future operations, plans and objectives of management are forward-looking statements. Examples of such statements include, but are not limited to, statements relating to (i) the timing of topline results from the ApproaCH Trial, (ii) Ascendis’ expectations regarding full year 2024 SKYTROFA revenue, (iii) Ascendis’ expectations regarding SKYTROFA’s potential to reach blockbuster status, (iv) Ascendis’ plan to submit a supplemental Biologics License Application for SKYTROFA for adult growth hormone deficiency in the third quarter of 2024, (v) the timing of topline results from the Phase 2 trial of TransCon hGH in Turner syndrome, (vi) Ascendis’ plan to submit a New Drug Application for TransCon CNP for children with achondroplasia, (vii) Ascendis’ expectations regarding completing manufacturing of YORVIPATH commercial product for the U.S. market and the timing of initial supply, (viii) dialogue with FDA regarding commercialization of existing YORVIPATH manufactured product and, if agreed, the potential timing of introduction, (ix) Ascendis’ expectations regarding initial revenue in France from YORVIPATH, (x) Ascendis’ plan to complete enrollment in the COACH Trial, (xi) the timing of topline Week 26 data from the COACH Trial, (xii) the timing of initiating the teACH Phase 2 trial in adolescents, (xiii) Ascendis’ plan to present initial results from the Phase 2 dose expansion cohort of the IL-Believe Trial, (xiv) Ascendis’ expectations regarding its total operating expenses for 2024, (xv) Ascendis’ expectation to be operating cash flow breakeven on a quarterly basis in 2024 or 2025, (xvi) Ascendis’ ability to apply its TransCon technology platform to build a leading, fully integrated biopharma company, and (xvii) Ascendis’ use of its TransCon technologies to create new and potentially best-in-class therapies. Ascendis may not actually achieve the plans, carry out the intentions or meet the expectations or projections disclosed in the forward-looking statements and you should not place undue reliance on these forward-looking statements. Actual results or events could differ materially from the plans, intentions, expectations and projections disclosed in the forward-looking statements. Various important factors could cause actual results or events to differ materially from the forward-looking statements that Ascendis makes, including the following: dependence on third party manufacturers, distributors and service providers for Ascendis’ products and product candidates; unforeseen safety or efficacy results in Ascendis’ development programs or on-market products; unforeseen expenses related to commercialization of any approved Ascendis products; unforeseen expenses related to Ascendis’ development programs; unforeseen selling, general and administrative expenses, other research and development expenses and Ascendis’ business generally; delays in the development of its programs related to manufacturing, regulatory requirements, speed of patient recruitment or other unforeseen delays; Ascendis’ ability to obtain additional funding, if needed, to support its business activities; the impact of international economic, political, legal, compliance, social and business factors. For a further description of the risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking statements, as well as risks relating to Ascendis’ business in general, see Ascendis’ Annual Report on Form 20-F filed with the U.S. Securities and Exchange Commission (SEC) on February 7, 2024 and Ascendis’ other future reports filed with, or submitted to, the SEC. Forward-looking statements do not reflect the potential impact of any future licensing, collaborations, acquisitions, mergers, dispositions, joint ventures, or investments that Ascendis may enter into or make. Ascendis does not assume any obligation to update any forward-looking statements, except as required by law.
Ascendis, Ascendis Pharma, the Ascendis Pharma logo, the company logo, TransCon, SKYTROFA®, and YORVIPATH® are trademarks owned by the Ascendis Pharma group. © September 2024 Ascendis Pharma A/S.
| Investor Contacts: | Media Contact: |
| Tim Lee | Melinda Baker |
| Ascendis Pharma | Ascendis Pharma |
| +1 (650) 374-6343 | +1 (650) 709-8875 |
| tle@ascendispharma.com | media@ascendispharma.com |
| ir@ascendispharma.com | |
| Patti Bank | |
| ICR Westwicke | |
| +1 (415) 513-1284 | |
| patti.bank@westwicke.com |
FINANCIAL TABLES FOLLOW
| Ascendis Pharma A/S Consolidated Statements of Profit or Loss and Comprehensive Income / (Loss) (In EUR'000s, except share and per share data) | Three Months Ended June 30, | Six Months Ended June 30, | |||||||||||||
| 2024 | 2023 | 2024 | 2023 | ||||||||||||
| Consolidated Statement of Profit or Loss | |||||||||||||||
| Revenue | 35,998 | 47,393 | 131,892 | 80,982 | |||||||||||
| Cost of sales | 11,465 | 12,929 | 19,034 | 17,551 | |||||||||||
| Gross profit | 24,533 | 34,464 | 112,858 | 63,431 | |||||||||||
| Research and development costs | 83,478 | 105,021 | 154,165 | 211,134 | |||||||||||
| Selling, general and administrative expenses | 74,312 | 70,281 | 141,095 | 136,820 | |||||||||||
| Operating profit/(loss) | (133,257 | ) | (140,838 | ) | (182,402 | ) | (284,523 | ) | |||||||
| Share of profit/(loss) of associate | (5,322 | ) | (7,451 | ) | (11,118 | ) | (8,677 | ) | |||||||
| Finance income | 49,052 | 35,761 | 14,395 | 80,374 | |||||||||||
| Finance expenses | 19,624 | 9,334 | 58,553 | 18,652 | |||||||||||
| Profit/(loss) before tax | (109,151 | ) | (121,862 | ) | (237,678 | ) | (231,478 | ) | |||||||
| Income taxes/(expenses) | (229 | ) | 429 | (2,737 | ) | (868 | ) | ||||||||
| Net profit/(loss) for the period | (109,380 | ) | (121,433 | ) | (240,415 | ) | (232,346 | ) | |||||||
| Attributable to owners of the Company | (109,380 | ) | (121,433 | ) | (240,415 | ) | (232,346 | ) | |||||||
| Basic and diluted earnings/(loss) per share | € | (1.91 | ) | € | (2.16 | ) | € | (4.21 | ) | € | (4.14 | ) | |||
| Number of shares used for calculation (basic and diluted) | 57,345,613 | 56,218,257 | 57,114,435 | 56,155,441 | |||||||||||
| (EUR’000) | |||||||||||||||
| Consolidated Statement of Comprehensive Income or (Loss) | |||||||||||||||
| Net profit/(loss) for the period | (109,380 | ) | (121,433 | ) | (240,415 | ) | (232,346 | ) | |||||||
| Items that may be reclassified subsequently to profit or loss: | |||||||||||||||
| Exchange differences on translating foreign operations | 15 | (1,016 | ) | 78 | (1,803 | ) | |||||||||
| Other comprehensive income/(loss) for the period, net of tax | 15 | (1,016 | ) | 78 | (1,803 | ) | |||||||||
| Total comprehensive income/(loss) for the period, net of tax | (109,365 | ) | (122,449 | ) | (240,337 | ) | (234,149 | ) | |||||||
| Attributable to owners of the Company | (109,365 | ) | (122,449 | ) | (240,337 | ) | (234,149 | ) | |||||||
| Ascendis Pharma A/S Consolidated Statements of Financial Position (In EUR'000s) | June 30, 2024 | December 31, 2023 | |||
| Assets | |||||
| Non-current assets | |||||
| Intangible assets | 4,186 | 4,419 | |||
| Property, plant and equipment | 104,041 | 110,634 | |||
| Investment in associates | 20,564 | 5,686 | |||
| Other receivables | 2,186 | 2,127 | |||
| 130,977 | 122,866 | ||||
| Current assets | |||||
| Inventories | 251,199 | 208,931 | |||
| Trade receivables | 49,163 | 35,874 | |||
| Income tax receivables | 1,841 | 802 | |||
| Other receivables | 29,679 | 19,097 | |||
| Prepayments | 36,743 | 38,578 | |||
| Marketable securities | — | 7,275 | |||
| Cash and cash equivalents | 258,696 | 392,164 | |||
| 627,321 | 702,721 | ||||
| Total assets | 758,298 | 825,587 | |||
| Equity and liabilities | |||||
| Equity | |||||
| Share capital | 7,819 | 7,749 | |||
| Distributable equity | (328,952 | ) | (153,446 | ) | |
| Total equity | (321,133 | ) | (145,697 | ) | |
| Non-current liabilities | |||||
| Borrowings | 219,052 | 222,996 | |||
| Contract liabilities | 5,000 | 5,949 | |||
| Deferred tax liabilities | 7,644 | 5,830 | |||
| 231,696 | 234,775 | ||||
| Current liabilities | |||||
| Convertible notes, matures in April 2028 | |||||
| Borrowings | 432,190 | 407,095 | |||
| Derivative liabilities | 159,059 | 143,296 | |||
| 591,249 | 550,391 | ||||
| Other current liabilities | |||||
| Borrowings | 21,397 | 14,174 | |||
| Contract liabilities | 1,293 | 1,184 | |||
| Trade payables and accrued expenses | 99,527 | 94,566 | |||
| Other liabilities | 26,411 | 41,176 | |||
| Income tax payables | 1,090 | 2,299 | |||
| Provisions | 106,768 | 32,719 | |||
| 256,486 | 186,118 | ||||
| 847,735 | 736,509 | ||||
| Total liabilities | 1,079,431 | 971,284 | |||
| Total equity and liabilities | 758,298 | 825,587 | |||
FAQ
What was Ascendis Pharma's (ASND) Q2 2024 revenue?
What is the revised 2024 revenue outlook for SKYTROFA?
When does Ascendis Pharma (ASND) expect to launch YORVIPATH in the U.S.?
What was Ascendis Pharma's (ASND) net loss for Q2 2024?
When does Ascendis Pharma (ASND) expect to achieve operating cash flow breakeven?
